Caesars Entertainment has secured a multi-year licensing deal with MLB Players, Inc., allowing Caesars Sportsbook and William Hill Nevada to use MLB player imagery in their marketing efforts. This agreement aims to enhance fan engagement by featuring actual players in their mobile apps and retail locations. The new MLB season began on March 25, and Caesars Entertainment Inc. (NASDAQ:CZR) shares saw a gain following the news.

Waton Financial (NASDAQ: WTF) celebrates its first anniversary as a listed company by introducing MOTA (Manager of Trading Agents), a platform designed for human-AI investment collaboration. Unlike other AI trading tools, MOTA focuses on regulated infrastructure, embedded compliance, and human oversight, emphasizing that AI suggests while humans decide. The company positions MOTA to address the missing conversation around licensing and accountability in the AI trading industry, aligning with evolving global AI regulations.

Starbucks recently integrated ordering capabilities within ChatGPT, allowing users to select coffee based on mood before being redirected to the app to complete the purchase. This strategy addresses income statement pressures by leveraging AI to reduce operational costs through its "Green Apron Assistant" and improve customer acquisition efficiency. While the stock has seen modest gains, its future performance hinges on the AI initiatives effectively impacting profitability and customer acquisition amidst challenges like technical costs, data integration complexities, and the sustainability of AI-driven advantages.

Xilio Therapeutics (Nasdaq: XLO) has appointed Cheryl R. Blanchard, Ph.D., a biotech veteran with over 30 years of experience, to its board of directors, effective April 16, 2026. Dr. Blanchard's expertise in biologics, devices, and commercial strategy, including her current role as executive chair of Anika, is expected to support Xilio's masked immuno-oncology pipeline. This appointment follows the departure of Christina Rossi from the board on April 15, 2026.

Aehr Test Systems (NASDAQ: AEHR) received a record $41 million production order from its lead hyperscale AI customer for package-level burn-in of custom AI processor ASICs. This order pushes Aehr's second-half bookings past $92 million, significantly exceeding prior expectations of $60-$80 million. Deliveries for this order are expected to begin in fiscal 2027, starting June 27, 2026, and the company has also expanded its manufacturing capacity to support this growing demand.

Aehr Test Systems announced a record $41 million follow-on production order from its lead hyperscale customer for package-level burn-in of custom AI processor ASICs, bringing its second-half fiscal year bookings to over $92 million. This order validates the Sonoma platform for high-volume burn-in of AI processor ASICs, and the company projects further demand as customers develop higher-power AI accelerators. Aehr has also expanded its production capacity to meet growing demand across various markets including AI, silicon photonics, and silicon carbide.

Woori Financial Group is considering the integration of Tongyang Life Insurance Co., Ltd. and ABL Life Insurance Co., Ltd., potentially making Tongyang Life Insurance a wholly owned subsidiary. These moves aim to strengthen Woori's competitiveness in the insurance sector, though no final decisions have been made. The company has committed to providing further updates within three months.

Abbott marginally beat Wall Street's first-quarter profit and revenue estimates, driven by its new cancer diagnostics business and strong medical device unit performance. Despite this, the company's shares fell 2% after it announced a 20-cent hit to its 2026 profit forecast due to the $23 billion acquisition of Exact Sciences. CEO Robert Ford stated that the acquisition still adds a high-growth business to Abbott's portfolio.

Abbott announced its first-quarter 2026 financial results, with sales increasing 7.8 percent on a reported basis and 3.7 percent on a comparable basis, and adjusted diluted EPS of $1.15. The company also updated its full-year 2026 guidance to reflect the recent acquisition of Exact Sciences, projecting comparable sales growth of 6.5% to 7.5% and adjusted diluted EPS of $5.38 to $5.58. This acquisition establishes Abbott as a leader in the oncology diagnostics market, further strengthening its growth prospects.

BMO Capital analyst Michael Zaremski has increased the price target for Progressive Corp. (PGR) to $221. This article is a premium-only piece, requiring a subscription to StreetInsider.com to read the full details. The update was made on April 16, 2026.